Genomic Landscapes of Pancreatic Neoplasia

키워드

참고문헌 (73)

1. Almoguera C, "Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes", Cell, 53, pp.549~554 (1988)
2. Smit VT, "KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas", Nucleic Acids Res, 16, pp.7773~7782 (1988)
3. Hruban RH, "K-ras oncogene activation in adenocarcinoma of the human pancreas: a study of 82carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization", Am J Pathol, 143, pp.545~554 (1993)
4. Schutte M, "Abrogation of the Rb", p16tumor-suppressive pathway in virtually all pancreatic carcinomas, 1997, pp.57, 3126~3130
5. Rozenblum E, "Tumor-suppressive pathways in pancreatic carcinoma", Cancer Res, 57, pp.1731~1734 (1997)
6. Jones S, "Core signaling pathways in human pancreatic cancers revealed by global genomic analyses", Science, 321, pp.1801~1806 (2008)
7. Iacobuzio-Donahue CA, "Missense mutations of MADH4 : characterization of the mutational hot spot and functional consequences in human tumors", Clin Cancer Res, 10, pp.1597~1604 (2004)
8. Wilentz RE, "Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation", Am J Pathol, 156, pp.37~43 (2000)
9. Blackford A, "SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer", Clin Cancer Res, 15, pp.4674~4679 (2009)
10. Iacobuzio-Donahue CA, "DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer", J Clin Oncol, 27, pp.1806~1813 (2009)
11. Yachida S, "Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors", Clin Cancer Res, 18, pp.6339~6347 (2012)
12. Biankin AV, "Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes", Nature, 491, pp.399~405 (2012)
13. Yachida S, "Distant metastasis occurs late during the genetic evolution of pancreatic cancer", Nature, 467, pp.1114~1117 (2010)
14. Lennon AM, "The early detection of pancreatic cancer: what will it take to diagnose and treat curable pancreatic neoplasia?", Cancer Res, 74, pp.3381~3389 (2014)
15. Sato N, "Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays", Cancer Res, 63, pp.3735~3742 (2003)
16. Bloomston M, "MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis", JAMA, 297, pp.1901~1908 (2007)
17. Lee EJ, "Expression profiling identifies microRNA signature in pancreatic cancer", Int J Cancer, 120, pp.1046~1054 (2007)
18. Szafranska AE, "MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma", Oncogene, 26, pp.4442~4452 (2007)
19. Griffin CA, "Consistent chromosome abnormalities in adenocarcinoma of the pancreas", Cancer Res, 55, pp.2394~2399 (1995)
20. Iacobuzio-Donahue CA, "Large-scale allelotype of pancreaticobiliary carcinoma provides quantitative estimates of genome-wide allelic loss", Cancer Res, 64, pp.871~875 (2004)
21. Birnbaum DJ, "Genome profiling of pancreatic adenocarcinoma", Genes Chromosomes Cancer, 50, pp.456~465 (2011)
22. Liu C, "The UPF1 RNA surveillance gene is commonly mutated in pancreatic adenosquamous carcinoma", Nat Med, 20, pp.596~598 (2014)
23. Brody JR, "Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma", Mod Pathol, 22, pp.651~659 (2009)
24. Wu J, "Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development", Sci Transl Med, 3, pp.92ra66~ (2011)
25. Wilentz RE, "Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas:a newly described and characterized entity", Am J Pathol, 156, pp.1641~1651 (2000)
26. Goggins M, "Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wildtype K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+", Am J Pathol, 152, pp.1501~1507 (1998)
27. Winter JM, "Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer", Clin Cancer Res, 14, pp.412~418 (2008)
28. Whitcomb D, "Germ-line mutations, pancreatic inflammation, and pancreatic cancer", Clin Gastroenterol Hepatol, 7(11Suppl), pp.S29~S34 (2009)
29. Bellin MD, "Total pancreatectomy and islet autotransplantation in chronic pancreatitis : recommendations from PancreasFest", Pancreatology, 14, pp.27~35 (2014)
30. van der Rhee JI, "Surveillance of second degree relatives from melanoma families with a CDKN2A germline mutation", Cancer Epidemiol Biomarkers Prev, 22, pp.1771~1777 (2013)
31. Lynch HT, "Pancreatic cancer and the FAMMM syndrome", Fam Cancer, 7, pp.103~112 (2008)
32. Lowery MA, "An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation:clinical descriptors, treatment implications, and future directions", Oncologist, 16, pp.1397~1402 (2011)
33. O’Sullivan CC, "Beyond breast and ovarian cancers: PARP inhibitors for BRCA mutation-associated and BRCA-like solid tumors", Front Oncol, 4, pp.42~ (2014)
34. Kanda M, "Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia", Gastroenterology, 142, pp.730~3.e9 (2012)
35. Wilentz RE, "Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia : evidence that DPC4 inactivation occurs late in neoplastic progression", Cancer Res, 60, pp.2002~2006 (2000)
36. Maitra A, "Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray", Mod Pathol, 16, pp.902~912 (2003)
37. van Heek NT, "Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia", Am J Pathol, 161, pp.1541~1547 (2002)
38. Murphy SJ, "Genetic alterations associated with progression from pancreatic intraepithelial neoplasia to invasive pancreatic tumor", Gastroenterology, 145, pp.1098~109.e1 (2013)
39. Amato E, "Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas", J Pathol, 233, pp.217~227 (2014)
40. Biankin AV, "Aberrant p16(INK4A)and DPC4", Smad4 expression in intraductal papillary mucinous tumours of the pancreas is associated with invasive ductal adenocarcinoma, 2002, pp.50, 861~868
41. Iacobuzio-Donahue CA, "Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas : comparison with conventional ductal adenocarcinomas", Am J Pathol, 157, pp.755~761 (2000)
42. Satoh K, "K-ras mutation and p53 protein accumulation in intraductal mucin-hypersecreting neoplasms of the pancreas", Pancreas, 12, pp.362~368 (1996)
43. Kawahira H, "p53 protein expression in intraductal papillary mucinous tumors(IPMT)of the pancreas as an indicator of tumor malignancy", Hepatogastroenterology, 47, pp.973~977 (2000)
44. Chadwick B, "Histologic, immunohistochemical, and molecular classification of 52 IPMNs of the pancreas", Appl Immunohistochem Mol Morphol, 17, pp.31~39 (2009)
45. Lubezky N, "High-throughput mutation profiling in intraductal papillary mucinous neoplasm (IPMN)", J Gastrointest Surg, 15, pp.503~511 (2011)
46. Dal Molin M, "Clinicopathological correlates of activating GNAS mutations in intraductal papillary mucinous neoplasm(IPMN)of the pancreas", Ann Surg Oncol, 20, pp.3802~3808 (2013)
47. Wu J, "Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways", Proc Natl Acad Sci U S A, 108, pp.21188~21193 (2011)
48. Schönleben F, "PIK3CA mutations in intraductal papillary mucinous neoplasm", carcinoma of the pancreas, 2006, pp.12, 3851~3855
49. Sato N, "STK11", LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas, 2001, pp.159, 2017~2022
50. Yip-Schneider MT, "Vascular endothelial growth factor, a novel and highly accurate pancreatic fluid biomarker for serous pancreatic cysts", J Am Coll Surg, 218, pp.608~617 (2014)
51. Moore PS, "Molecular characterization of pancreatic serous microcystic adenomas: evidence for a tumor suppressor gene on chromosome 10q", Am J Pathol, 158, pp.317~321 (2001)
52. Reddy S, "Surgical management of solid-pseudopapillary neoplasms of the pancreas(Franz or Hamoudi tumors) : a large single-institutional series", J Am Coll Surg, 208, pp.950~957 (2009)
53. Law JK, "A systematic review of solid-pseudopapillary neoplasms: are these rare lesions?", Pancreas, 43, pp.331~337 (2014)
54. Abraham SC, "Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations", Am J Pathol, 160, pp.1361~1369 (2002)
55. Tanaka Y, "Frequent beta-catenin mutation and cytoplasmic", nuclear accumulation in pancreatic solid-pseudopapillary neoplasm, 2001, pp.61, 8401~8404
56. McCall CM, "Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate", Am J Surg Pathol, 37, pp.1671~1677 (2013)
57. Jiao Y, "DAXX", ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors, 2011, pp.331, 1199~1203
58. Öberg K., "The genetics of neuroendocrine tumors", Semin Oncol, 40, pp.37~44 (2013)
59. Heaphy CM, "Altered telomeres in tumors with ATRX and DAXX mutations", Science, 333, pp.425~ (2011)
60. de Wilde RF, "Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors", Mod Pathol, 25, pp.1033~1039 (2012)
61. Yao JC, "Everolimus for advanced pancreatic neuroendocrine tumors", N Engl J Med, 364, pp.514~523 (2011)
62. Serrano J, "Alterations in the p16INK4a", CDKN2A tumor suppressor gene in gastrinomas, 2000, pp.85, 4146~4156
63. Bartsch D, "Mutations of the DPC4", Smad4 gene in neuroendocrine pancreatic tumors, 1999, pp.18, 2367~2371
64. Yachida S, "Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors", Am J Surg Pathol, 36, pp.173~184 (2012)
65. Wood LD, "Pathology and genetics of pancreatic neoplasms with acinar differentiation", Semin Diagn Pathol, 31, pp.491~497 (2014)
66. Jiao Y, "Whole-exome sequencing of pancreatic neoplasms with acinar differentiation", J Pathol, 232, pp.428~435 (2014)
67. Abraham SC, "Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC", beta-catenin pathway, 2002, pp.160, 953~962
68. Chmielecki J, "Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes", Cancer Discov, 4, pp.1398~1405 (2014)
69. Abraham SC, "Distinctive molecular genetic alterations in sporadic and familial adenomatous polyposisassociated pancreatoblastomas : frequent alterations in the APC", beta-catenin pathway and chromosome 11p, 2001, pp.159, 1619~1627
70. Wiley J, "Cytogenetic and flow cytometric analysis of a pancreatoblastoma", Cancer Genet Cytogenet, 79, pp.115~118 (1995)
71. Nagashima Y, "Pancreatoblastoma: a second report on cytogenetic findings", Cancer Genet Cytogenet, 109, pp.178~179 (1999)
72. Barenboim-Stapleton L, "Pediatric pancreatoblastoma:histopathologic and cytogenetic characterization of tumor and derived cell line", Cancer Genet Cytogenet, 157, pp.109~117 (2005)
73. Wang CL, "Fluorescence in situ hybridization analysis of pancreatoblastoma", Pancreas, 38, pp.223~224 (2009)

관련 논문AI추천